Company: KROS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001664710-25-000070
Chunk: 407

Company: Keros Therapeutics, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 8
Chunk 407
---
 or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. 

We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:

■variations in the level of expense related to the ongoing development of our product candidates and preclinical and clinical development programs; 

■results of preclinical studies and ongoing and future clinical trials, or the addition or termination of clinical trials or funding support by us, or current or future collaborators or licensing partners; 

■our execution of any collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under existing or future arrangements or the termination or modification of any such existing or future arrangements; 

■any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may become involved; 

■additions and departures of key personnel; 

81

■strategic decisions by us, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy; 

■if any of our product candidates receives regulatory approval, the terms of such approval and market acceptance and demand for such product candidates; 

■regulatory developments affecting our product candidates; and

■general economic conditions, including as a result of bank failures, as well as economic conditions specifically affecting the biopharmaceutical industry. 

If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our common stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. 

The market price of our common stock has been and is likely to continue to be volatile and fluctuate substantially. 

The market price of our common stock has been and is likely to continue to be highly volatile and may fluctuate substantially as a result of a variety of factors, some of which are related in complex ways. The market price for our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including the factors listed below and other factors described in this “Risk Factors” section: 

■results of preclinical studies and clinical trials of KER-065, elritercept and any other product candidate we may develop or those of our competitors; 

■actual or anticipated